Proliferative Diabetic Retinopathy Clinical Trial
Official title:
A Randomised Control Trial Comparing the Effectiveness of Yellow 577 nm Laser to Conventional Green 532 nm Laser for Proliferative Diabetic Retinopathy
The purpose of this study is to measure effectiveness of yellow 577 nm laser compared to
conventional green laser 532 nm for diabetic retinopathy in terms of number of treatment
sessions required and visual acuity outcome.
The study also compares pain score of patients receiving laser treatment and side effects of
laser treatment.
Diabetes mellitus (DM) is a major medical problem throughout the world. The most common and
potentially most blinding of these complications is proliferative diabetic retinopathy
(PDR).
Panretinal photocoagulation is established as the gold standard of treatment, supported by
the data of the Diabetic Retinopathy Study (DRS).This study found that laser treatment
reduced the rate of severe visual loss by 50%. Currently the green 532nm laser is the most
common wavelength used. However, this conventional green laser has some complications such
as pain, vitreous haemorrhage, choroidal effusion and visual field loss.
Due to the complication of conventional lasers, the yellow laser (577 nm)with peak
absorption of oxyhemoglobin and good absorption of melanin is postulated to be more
effective at producing retinal laser burns with a lower power and less pain compared to the
green laser.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
Completed |
NCT02879422 -
Genetic Markers and Proliferative Diabetic Retinopathy
|
N/A | |
Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 | |
Completed |
NCT02858076 -
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
|
Phase 2/Phase 3 |